Difference between revisions of "Team:CGU Taiwan"

Line 220: Line 220:
 
</div>
 
</div>
  
<div class="end" style="top:250%;">
+
<div class="end" style="top:200%;">
 
<div style="font-size:20px;color:white;text-decoration:none;margin-left:20%;margin-top:5%;">
 
<div style="font-size:20px;color:white;text-decoration:none;margin-left:20%;margin-top:5%;">
 
Chang Gung University
 
Chang Gung University

Revision as of 15:43, 28 November 2016







Abstract




Leijuvant- A Revolutionary Choice of Vaccine Helper
For many infectious diseases that still don’t have an effective vaccine, enhancing T cell immune response may be the key point to solve this problem. Leijuvant represents a whole new perspective of adjuvant that uses Leishmania as an effective T cell stimulator. Leishmania is a parasite that specifically lives within macrophage, a professional antigen presenting cell (APC). As a potential vaccine adjuvant, Leishmania possess many advantages, including APC recruitment, pattern recognition receptor (PRR) activation, inflammasome activation, activation of MHC-presenting pathway and most important of all, T cell activation. Genetically-engineered Leishmania that can be inactivated by light exposure acts as a safe carrier to deliver specific antigens to APCs for activation of T cells and B cell stimulation. Based on this concept, we established a new model system to generate antigen-specific Leishmania adjuvant-- Leijuvant. We further designed a user-friendly MHC peptide prediction software to integrate key protein information and optimize the presentation of antigen peptides by MHC molecules. Our ultimate goal is to introduce Leijuvant as an effective, safe, and antigen-specific adjuvant to the vaccine industry and the general public.


Start Our Journey




PROJECT

NEWS

RESULTS

Chang Gung University

No.259, Wenhua 1st Rd., Guishan Dist., Taoyuan City 33302, Taiwan (R.O.C.)
TEL: +886-3-2118800 FAX:+886-3-2118700